Unleash Immuno Oncolytics (RNAZ holder) reports 9.94% TransCode Therapeutics stake

Rhea-AI Filing Summary

TransCode Therapeutics, Inc. has a significant shareholder, Unleash Immuno Oncolytics, Inc., which reported beneficial ownership of 300,000 shares of common stock. This represents 9.94% of the outstanding class, with sole voting and sole dispositive power over all 300,000 shares.

Key Figures

Shares beneficially owned: 300,000 shares Percent of class: 9.94% Sole voting power: 300,000 shares +3 more

6 metrics

Shares beneficially owned 300,000 shares Common stock of TransCode Therapeutics, Inc. reported by Unleash Immuno Oncolytics, Inc.

Percent of class 9.94% Percentage of TransCode Therapeutics common stock class held by Unleash Immuno Oncolytics, Inc.

Sole voting power 300,000 shares Shares for which Unleash Immuno Oncolytics, Inc. holds sole power to vote or direct the vote

Sole dispositive power 300,000 shares Shares for which Unleash Immuno Oncolytics, Inc. holds sole power to dispose or direct disposition

Shared voting power 0 shares No shares reported with shared power to vote or direct the vote

Shared dispositive power 0 shares No shares reported with shared power to dispose or direct disposition

Key Terms

beneficially owned, sole voting power, sole dispositive power, percent of class, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 300,000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"5 | Sole Voting Power 300,000.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"7 | Sole Dispositive Power 300,000.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"Item 4. | Ownership (a) | Amount beneficially owned: 300,000 (b) | Percent of class: 9.94%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Schedule 13G regulatory

"form_type: "SCHEDULE 13G""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 07:52 PM Accepted by SEC EDGAR 07/28/2026 - 07:51 PM Learn about SEC filing dates

FAQ

What stake in TransCode Therapeutics (RNAZ) does Unleash Immuno Oncolytics report on this Schedule 13G?

Unleash Immuno Oncolytics reports beneficial ownership of 300,000 shares of TransCode Therapeutics common stock, representing 9.94% of the class. This makes it a significant shareholder with a sizable, though non-controlling, position in the company.

Does Unleash Immuno Oncolytics have voting control over its RNAZ shares?

Unleash Immuno Oncolytics reports sole voting power over 300,000 shares of TransCode Therapeutics and no shared voting power. This means it alone decides how these shares are voted, without disclosed joint control arrangements.

What dispositive power does Unleash Immuno Oncolytics have over RNAZ shares?

The filing states Unleash Immuno Oncolytics has sole dispositive power over 300,000 shares and no shared dispositive power. It can independently decide when and how to sell or otherwise dispose of these shares.

How close is Unleash Immuno Oncolytics’ ownership in RNAZ to the 10% threshold?

Unleash Immuno Oncolytics reports owning 9.94% of TransCode Therapeutics’ common stock. This percentage is just below the 10% level often referenced in U.S. securities reporting requirements for larger shareholders.

Where is Unleash Immuno Oncolytics, the RNAZ shareholder, organized and located?

Unleash Immuno Oncolytics is incorporated in Delaware and lists its principal business office at 990 Biscayne Boulevard, Suite 502, Miami, FL 33132. The company files as a U.S. entity holding TransCode Therapeutics shares.

Who signed the beneficial ownership report related to RNAZ on behalf of Unleash Immuno Oncolytics?

The report is signed by Daniel Eduardo Katzman, identified as Chief Executive Officer of Unleash Immuno Oncolytics. His electronic signature appears with a date of 07/28/2026 on the ownership disclosure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TransCode Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

89357L501

(CUSIP Number)

07/23/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 89357L501

1

Names of Reporting Persons

Unleash Immuno Oncolytics, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 300,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 300,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

300,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.94 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TransCode Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6 Liberty Square, #2382, Boston, Massachusetts, 02109
Item 2.
(a)	Name of person filing: Unleash Immuno Oncolytics, Inc.
(b)	Address or principal business office or, if none, residence: 990 Biscayne Boulevard, Suite 502 Miami, FL 33132
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 89357L501
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 300,000
(b)	Percent of class: 9.94%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 300,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 300,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Unleash Immuno Oncolytics, Inc.

Signature:	/s/Daniel Eduardo Katzman
Name/Title:	Daniel Eduardo Katzman/Chief Executive Officer
Date:	07/28/2026